A new therapeutic strategy is pursued by the monoclonal antibody from Biotest, which is currently in clinical development. BT-062 stands for a modern treatment strategy against cancer, which takes direct aim at tumor cells, while largely sparing healthy cells (see Fig.).

Based on current knowledge, Biotest assumes that this antibody will have a particularly efficient and safe effect. The antibody was already able to prove its efficacy in animal models. Safety and tolerability was examined in a Phase I study at 4 US centers determining the maximum tolerated dose (MTD), but which also gives an initial evidence of clinical activity. Based on the encouraging results observed in the trial, Biotest continued with the development of BT-062 and initiated a P I/IIa trial, with a more intensive dosage schedule. This dose escalation trial focus on repeated, multi-dose, intravenous dosing of BT-062. Patient recruitment is in progress. (Development status) 

Since the target molecule of BT-062 is located not only on the multiple myeloma cells but also on other tumor cell types, Biotest assumes that the scope of indications  of the Biotest antibody will be extended in the future.